Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax, Inc. (Nasdaq: NVAX) has enrolled the first participants in a Phase 1/2 study assessing the safety and immunogenicity of a combined vaccine for COVID-19 and seasonal influenza. This innovative COVID-NanoFlu Combination Vaccine utilizes Novavax' recombinant protein-based NVX-CoV2373 and NanoFlu™ candidates, enhanced by the Matrix-M™ adjuvant. The trial, set to involve 640 healthy adults aged 50 to 70, will take place across Australia, with results anticipated in the first half of 2022.
Novavax, a biotechnology company focused on next-generation vaccines, announced its participation in Citi's 16th Annual BioPharma Virtual Conference on September 9, 2021. The event will feature a fireside chat discussing Novavax' COVID-19 vaccine candidate, NVX-CoV2373. Key participants from Novavax, including Dr. Gregory M. Glenn and John J. Trizzino, will represent the company. A replay of the session will be available on Novavax's website for 90 days following the event.
The company continues its late-stage trials for NVX-CoV2373 and its influenza vaccine, NanoFlu.
Novavax, Inc. (Nasdaq: NVAX) announced that the CDC has updated guidance stating participants in the PREVENT-19 Phase 3 clinical trial can be considered fully vaccinated two weeks after completing the vaccine series. This recognition underscores the efficacy of Novavax's vaccine candidate, NVX-CoV2373, which demonstrated 90% overall efficacy and 100% protection against moderate and severe disease in the trial. The update ensures clarity for trial participants, highlighting their contributions to public health despite the vaccine's non-authorization by the FDA.
Novavax (Nasdaq: NVAX) has initiated the OCTAVE-DUO study in the UK to assess the safety and efficacy of a third COVID-19 vaccine dose for immunocompromised individuals. This study, funded by the UK government's Vaccines Taskforce, includes 320 participants with lymphoid malignancies who previously showed low or no response to two doses of a primary vaccine. One-third will receive Novavax's NVX-CoV2373 vaccine. Results are expected later in 2021, aiding insights into vaccination strategies for vulnerable populations.
On August 16, 2021, Novavax, Inc. (Nasdaq: NVAX) announced the appointment of Jim Kelly as Executive Vice President and Chief Financial Officer, and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance. Jim Kelly brings over 25 years of experience, previously serving as CFO at Supernus Pharmaceuticals and Vanda Pharmaceuticals. Nasir Egal, with extensive quality experience from Sanofi and Merck, will enhance Novavax's regulatory and commercial activities, particularly for its COVID-19 vaccine. This leadership change is aimed at strengthening Novavax's operational capabilities in the global vaccine market.
Novavax (NVAX) reported a significant net loss of $352 million for Q2 2021, translating to $4.75 per share, compared to a loss of $18 million in Q2 2020. Revenue surged to $298 million from $36 million, driven by development activities for NVX-CoV2373. R&D expenses skyrocketed to $571 million, up from $35 million year-over-year. The company holds $2.1 billion in cash as of June 30, 2021, facilitating ongoing vaccine development and regulatory submissions globally. Key vaccine advancements include 90.4% efficacy in the Phase 3 trial and plans to file for emergency authorizations in several markets.
Novavax (Nasdaq: NVAX) announced promising preliminary data from a Phase 2 study revealing that a single booster dose of its NVX-CoV2373 COVID-19 vaccine, administered six months after initial vaccination, resulted in a 4.6-fold increase in functional antibody titers. Additionally, the booster elicited a more than six-fold increase in antibodies against the Delta variant. The study underscored a favorable safety profile, with side effects primarily mild and transient. The full data will be submitted for peer review.
Novavax, in partnership with the Serum Institute of India, has filed for emergency use authorization for its recombinant nanoparticle COVID-19 vaccine in India, Indonesia, and the Philippines. This is the first protein-based COVID-19 vaccine submission to any regulatory body. A submission for World Health Organization Emergency Use Listing is expected in August 2021. The vaccine, NVX-CoV2373, shows high efficacy rates and is designed to be stable in standard cold chain conditions. Novavax and SII are committed to providing over 1.1 billion doses to the COVAX Facility.
Novavax (Nasdaq: NVAX) announced a significant agreement with the European Commission for up to 200 million doses of its COVID-19 vaccine, NVX-CoV2373, including an initial purchase of 100 million doses. Deliveries are set to commence post-approval from the European Medicines Agency, expected in Q3 2021. Clinical trials showed NVX-CoV2373's efficacy at 90.4% against overall infection and 100% against severe disease. This partnership aims to bolster vaccine options for Europe and globally amid the ongoing pandemic.
Novavax, Inc. (Nasdaq: NVAX) will announce its second quarter 2021 financial results and operational highlights on August 5, 2021, at 4:30 p.m. ET. The announcement will be followed by a conference call, accessible at www.novavax.com/events. Notably, Novavax is conducting late-stage clinical trials for its COVID-19 vaccine, NVX-CoV2373, and has achieved positive results with its NanoFlu™ vaccine for influenza, which met all primary objectives in its Phase 3 trial.